Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OMCL 
Omnicell Inc (OMCL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: OMCL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 6.81% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.64B USD | Price to earnings Ratio 129.48 | 1Y Target Price 51 |
Price to earnings Ratio 129.48 | 1Y Target Price 51 | ||
Volume (30-day avg) 591389 | Beta 0.85 | 52 Weeks Range 25.12 - 55.74 | Updated Date 04/1/2025 |
52 Weeks Range 25.12 - 55.74 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 1.13% | Operating Margin (TTM) 4.49% |
Management Effectiveness
Return on Assets (TTM) 0.16% | Return on Equity (TTM) 1.03% |
Valuation
Trailing PE 129.48 | Forward PE 29.5 | Enterprise Value 1636046707 | Price to Sales(TTM) 1.47 |
Enterprise Value 1636046707 | Price to Sales(TTM) 1.47 | ||
Enterprise Value to Revenue 1.47 | Enterprise Value to EBITDA 18.16 | Shares Outstanding 46759400 | Shares Floating 45517952 |
Shares Outstanding 46759400 | Shares Floating 45517952 | ||
Percent Insiders 1.69 | Percent Institutions 102.37 |
Analyst Ratings
Rating 3.78 | Target Price 55.43 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Omnicell Inc
Company Overview
History and Background
Omnicell Inc. was founded in 1992. It initially focused on developing automated medication dispensing systems for hospitals. Over time, it has expanded its product line and service offerings to encompass medication management solutions across the continuum of care.
Core Business Areas
- Medication Management Systems: Offers automated dispensing cabinets, IV automation, and central pharmacy automation solutions. These systems automate medication storage, dispensing, and tracking, improving accuracy and efficiency in hospitals and pharmacies.
- Medication Adherence: Provides solutions to improve patient adherence to medication regimens, including medication synchronization, home delivery, and adherence packaging. This segment focuses on helping patients manage their medications effectively outside of the hospital setting.
- Analytics and Intelligence: Offers data analytics and reporting tools to help healthcare providers gain insights into medication usage, costs, and outcomes. These tools enable data-driven decision-making to optimize medication management practices.
Leadership and Structure
Omnicell Inc. has a leadership team consisting of a CEO, CFO, and other key executives. The organizational structure is typically divided into functional departments such as sales, marketing, research and development, and operations.
Top Products and Market Share
Key Offerings
- Automated Dispensing Cabinets (ADCs): ADCs are automated medication dispensing systems used in hospitals to improve medication security and reduce medication errors. Competitors include BD (Becton, Dickinson and Company) and Capsa Healthcare. Omnicell is considered a market leader in this space. Market share data is difficult to pinpoint exactly but Omnicell is estimated to be a leading company within this space. Revenue can be estimated by assessing the Medical Automation/Robotics sub segment's total revenue.
- Central Pharmacy Automation: Provides robotic systems for automating medication dispensing in central pharmacies. This improves efficiency and reduces labor costs. Competitors include BD (Becton, Dickinson and Company), iRx and ARxIUM. Market share data is difficult to pinpoint exactly, but estimates are around 10-20% depending on the specific product within the category.
Market Dynamics
Industry Overview
The healthcare technology industry is experiencing growth due to factors such as increasing healthcare costs, aging populations, and the need for improved patient safety and efficiency. The industry is characterized by innovation and consolidation.
Positioning
Omnicell Inc. is positioned as a leading provider of medication management solutions, with a focus on automation, analytics, and patient adherence. Its competitive advantages include a broad product portfolio, a strong customer base, and a reputation for innovation.
Total Addressable Market (TAM)
The total addressable market (TAM) for medication management solutions is estimated to be tens of billions of dollars. Omnicell is positioned to capture a significant portion of this market through its comprehensive product portfolio and strong market presence.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Broad product portfolio
- Large customer base
- Innovative technology
- Good customer retention
Weaknesses
- High reliance on hospital spending
- Integration challenges with acquired companies
- Product recalls impacting customer trust
- High SG&A relative to some competitors
Opportunities
- Expanding into new markets (e.g., international)
- Developing new solutions for medication adherence
- Acquiring complementary technologies
- Partnerships with electronic health record (EHR) vendors
- Growth of telehealth further driving remote medication management
Threats
- Increased competition from larger companies
- Economic downturn impacting hospital budgets
- Regulatory changes affecting medication management
- Cybersecurity threats
- Reimbursement models pressuring pharmacy revenue
Competitors and Market Share
Key Competitors
- BDX
- MTD
- CAH
Competitive Landscape
Omnicell Inc. faces competition from larger healthcare companies and smaller niche players. Its advantages include a broad product portfolio and a strong brand reputation. Disadvantages include its smaller size compared to some competitors and its reliance on hospital spending.
Major Acquisitions
ReCeipt
- Year: 2021
- Acquisition Price (USD millions): 29
- Strategic Rationale: Enhanced central pharmacy automation with faster prescription processing, improved throughput, and reduced medication errors and costs.
Growth Trajectory and Initiatives
Historical Growth: Omnicell has demonstrated growth through product innovation, acquisitions, and expansion into new markets.
Future Projections: Analyst estimates vary, but generally project continued growth in revenue and earnings, driven by the demand for medication management solutions.
Recent Initiatives: Recent strategic initiatives may include acquisitions, product launches, partnerships, and investments in new technologies.
Summary
Omnicell is a leading provider of medication management solutions benefiting from increasing healthcare automation. Their strengths include a strong product portfolio and innovation. They face challenges from larger competitors and fluctuations in hospital spending. Recent acquisitions and partnerships position them for continued growth in a expanding market, but product recalls will reduce customer trust.
Similar Companies
BDX
Becton Dickinson and Company
BDX
Becton Dickinson and Company
CAH
Cardinal Health Inc
CAH
Cardinal Health Inc
MTD
Mettler-Toledo International Inc
MTD
Mettler-Toledo International Inc
Sources and Disclaimers
Data Sources:
- Company SEC filings (10-K, 10-Q)
- Industry reports
- Analyst estimates
- Company press releases
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Market share data is approximate and based on available estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Omnicell Inc
Exchange NASDAQ | Headquaters Fort Worth, TX, United States | ||
IPO Launch date 2001-08-07 | Founder, Executive Chairman, President & CEO Mr. Randall A. Lipps | ||
Sector Healthcare | Industry Health Information Services | Full time employees 3670 | Website https://www.omnicell.com |
Full time employees 3670 | Website https://www.omnicell.com | ||
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration. In addition, the company offers inventory optimization services comprising predictive and prescriptive analytics, benchmarking, workflow tools, and clinical resources, as well as medication inventory visibility; patient engagement, clinical, and financial solutions; medication adherence solutions, which include single-dose automation solutions, automated and semi-automated filling equipment, various medication blister card packaging and packaging supplies; and software that guides users through the manual filling process. Further, it provides professional services, such as technology installation, program management, customer education and training, change management services, and related offerings; technical services comprising post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; and retail pharmacy and hospital automation outside the United States business. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.